✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Eris Lifesciences Ltd.

ERIS

Market Cap
₹23,240 Cr.
P/E
66.05

Eris Lifesciences Ltd.

  • Eris Lifesciences
  • Astrazeneca Pharma I
  • JB Chem & Pharma
  • TJI Pharma - Small Cap
FAQs on Eris Lifesciences Ltd. Shareprice

Eris Lifesciences has given lower returns compared to its competitors.
Eris Lifesciences has grown at ~14.02% over the last 8yrs while peers have grown at a median rate of 15.28%

Yes, Eris Lifesciences is expensive.
Latest PE of Eris Lifesciences is 66.05, while 3 year average PE is 32.58.
Also latest EV/EBITDA of Eris Lifesciences is 25.01 while 3yr average is 20.79.

View FAQ's On Business
Growth Table
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Balance Sheet
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Cash Flow
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Quarterly Results
  • Eris Lifesciences Ltd.
  • Astrazeneca Pharma I
  • JB Chem & Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Eris Lifesciences Ltd. Financials

Balance sheet of Eris Lifesciences is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of Eris Lifesciences is increasing.
Latest net debt of Eris Lifesciences is ₹1,979 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹58.8 Crs.

The profit is oscillating.
The profit of Eris Lifesciences is ₹352 Crs for Mar 2025, ₹392 Crs for Mar 2024 and ₹382 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Eris Lifesciences latest dividend payout ratio is 28.45% and 3yr average dividend payout ratio is 27.3%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech